| Literature DB >> 32631212 |
Xiudong Shi1, Qinqin Yan1, Yi Zhan1, Chunzi Shi1, Fengxiang Song1, Lin Wang1, Tangkai Qi2, Hongzhou Lu2, Fei Shan1, Yuxin Shi1.
Abstract
The objective of this study was to evaluate whether combination antiretroviral therapy (cART) has an effect on the clinical manifestations, radiological characteristics, and disease severity of human immunodeficiency virus (HIV)-associated Talaromyces marneffei infection. The clinical manifestations, chest computed tomography (CT) images, and disease severity were compared between 14 patients with culture-confirmed T. marneffei infections who received cART and 38 patients who did not receive cART. Clinical manifestations included high fever (>38°C), cough, shortness of breath, chills, and skin rash. Chest CT scans were evaluated for the presence of ground-glass opacities, consolidation, miliary nodules, nodules, masses, cavitation, pericardial effusion, pleural effusion, mediastinal lymphadenitis, and the distribution of parenchymal abnormalities. Disease severity was estimated by clinical manifestations and chest CT findings. Fever (>38°C), cough, shortness of breath, and chills were significantly less frequent in patients who received cART than in those who did not receive cART (P < 0.05). The frequencies of miliary nodules, mediastinal lymphadenitis, and the proportion of diffuse lesions were significantly lower in patients who received cART than in those who did not receive cART (P < 0.05). The disease severity was significantly decreased in patients who received cART compared with patients who did not receive cART (P < 0.001). T. marneffei-infected patients who received cART had fewer clinical manifestations and decreased disease severity compared with those who did not receive this treatment. The use of cART is associated with modified chest CT characteristics in HIV-associated T. marneffei infections.Entities:
Keywords: HIV; Talaromyces marneffei; chest imaging; clinical manifestation; combination antiretroviral therapy
Mesh:
Year: 2020 PMID: 32631212 DOI: 10.1177/0956462420925248
Source DB: PubMed Journal: Int J STD AIDS ISSN: 0956-4624 Impact factor: 1.359